keyword
MENU ▼
Read by QxMD icon Read
search

Ramipril

keyword
https://www.readbyqxmd.com/read/28195948/early-treatment-with-zofenopril-and-ramipril-in-combination-with-acetyl-salicylic-acid-in-patients-with-left-ventricular-systolic-dysfunction-after-acute-myocardial-infarction-results-of-a-5-year-follow-up-of-patients-of-the-smile-4-study
#1
Claudio Borghi, Stefano Omboni, Salvatore Novo, Dragos Vinereanu, Giuseppe Ambrosio, Ettore Ambrosioni
The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) following acute myocardial infarction (AMI), early treatment with zofenopril plus acetyl salicylic acid (ASA) is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus ASA. We now report on CV outcomes during a 5-year follow-up of the patients of the SMILE-4 study. 386 of the 518 patients completing the study (51.2%) could be tracked after the study end and 265 could be included in the analysis...
February 13, 2017: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/28192475/adverse-cardiac-effects-of-exogenous-angiotensin-1-7-in-rats-with-subtotal-nephrectomy-are-prevented-by-ace-inhibition
#2
Louise M Burrell, Daniel Gayed, Karen Griggs, Sheila K Patel, Elena Velkoska
We previously reported that exogenous angiotensin (Ang) 1-7 has adverse cardiac effects in experimental kidney failure due to its action to increase cardiac angiotensin converting enzyme (ACE) activity. This study investigated if the addition of an ACE inhibitor (ACEi) to Ang 1-7 infusion would unmask any beneficial effects of Ang 1-7 on the heart in experimental kidney failure. Male Sprague-Dawley rats underwent subtotal nephrectomy (STNx) and were treated with vehicle, the ACEi ramipril (oral 1mg/kg/day), Ang 1-7 (subcutaneous 24 μg/kg/h) or dual therapy (all groups, n = 12)...
2017: PloS One
https://www.readbyqxmd.com/read/28155333/cardioprotective-role-of-zofenopril-in-hypertensive-patients-with-acute-myocardial-infarction-a-pooled-individual-data-analysis-of-the-smile-studies
#3
Claudio Borghi, Stefano Omboni, Giorgio Reggiardo, Stefano Bacchelli, Daniela Degli Esposti, Ettore Ambrosioni
PURPOSE: The four SMILE studies demonstrated that early administration of zofenopril following acute myocardial infarction is prognostically beneficial compared to placebo or other angiotensin-converting enzyme (ACE) inhibitors. In the present retrospective pooled analysis of individual SMILE studies, we evaluated the efficacy of zofenopril on cardiovascular (CV) outcomes in 1880 hypertensive and 1662 normotensive patients. MATERIALS AND METHODS: Four hundred and forty-nine hypertensives and 486 normotensives were treated with placebo, 980 and 786 with zofenopril 30-60 mg daily, 252 and 259 with lisinopril 5-10 mg daily, 199 and 131 with ramipril 10 mg daily, for 6 to 48 weeks...
February 3, 2017: Blood Pressure
https://www.readbyqxmd.com/read/28118402/effects-of-direct-renin-blockade-on-renal-systemic-hemodynamics-and-on-raas-activity-in-weight-excess-and-hypertension-a-randomized-clinical-trial
#4
A J Kwakernaak, L C Roksnoer, H J Lambers Heerspink, I van den Berg-Garrelds, G A Lochorn, J H van Embden Andres, M A Klijn, H Kobori, A H J Danser, G D Laverman, G J Navis
AIM: The combination of weight excess and hypertension significantly contributes to cardiovascular risk and progressive kidney damage. An unfavorable renal hemodynamic profile is thought to contribute to this increased risk and may be ameliorated by direct renin inhibition (DRI). The aim of this trial was to assess the effect of DRI on renal and systemic hemodynamics and on RAAS activity, in men with weight excess and hypertension. METHODS: A randomized, double-blind, cross-over clinical trial to determine the effect of DRI (aliskiren 300 mg/day), with angiotensin converting enzyme inhibition (ACEi; ramipril 10 mg/day) as a positive control, on renal and systemic hemodynamics, and on RAAS activity (n = 15)...
2017: PloS One
https://www.readbyqxmd.com/read/28094583/signal-detection-activity-on-eudravigilance-data-analysis-of-the-procedure-and-findings-from-an-italian-regional-centre-for-pharmacovigilance
#5
Luca Monaco, Mauro Melis, Chiara Biagi, Monia Donati, Ester Sapigni, Alberto Vaccheri, Domenico Motola
BACKGROUND: In July 2012 a new European legislation (Directive 2010/84/EU and Regulation No. 1235/2010) regarding pharmacovigilance has become effective. It has boosted the activity of Signal Detection through a monthly analysis of potential safety signals on EudraVigilance (EV). Our aim is to describe the procedure of signal detection on EV data and to present results obtained by the our pharmacovigilance centre. METHOD: Data are extracted from EV database, which collects suspected Adverse Drug Reactions (ADRs) of medicinal products in Europe...
January 17, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28045910/comparative-efficacy-and-safety-of-antihypertensive-agents-for-adult-diabetic-patients-with-microalbuminuric-kidney-disease-a-network-meta-analysis
#6
Rongzhong Huang, Yuxing Feng, Ying Wang, Xiaoxia Qin, Narayan Dhruvaraj Melgiri, Yang Sun, Xingsheng Li
BACKGROUND: Antihypertensive treatment mitigates the progression of chronic kidney disease. Here, we comparatively assessed the effects of antihypertensive agents in normotensive and hypertensive diabetic patients with microalbuminuric kidney disease. METHODS: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched for randomized controlled trials (RCTs) comparing oral antihypertensive agents in adult diabetic patients with microalbuminuria...
2017: PloS One
https://www.readbyqxmd.com/read/27993410/consensus-document-for-the-use-of-the-polypill-in-the-secondary-prevention-of-cardiovascular-disease
#7
José Ramón González-Juanatey, José María Mostaza, José María Lobos, Benjamín Abarca, José Luis Llisterri, Gonzalo Baron-Esquivias, Enrique Galve, Rosa María Lidón, Francisco Xavier Garcia-Moll, Pedro Luis Sánchez, Carmen Suárez, Jesús Millán, Vicente Pallares, José Juan Alemán, Isabel Egocheaga
Cardiovascular disease is a chronic disorder which is usually already at an advanced stage when the first symptoms develop. The fact that the initial clinical presentation can be lethal or highly incapacitating emphasizes the need for primary and secondary prevention. It is estimated that the ratio of patients with good adherence to secondary prevention of cardiovascular disease is low and also decreases gradually over time. The Polypill for secondary prevention of cardiovascular disease is the first fixed-dose combination therapy of salicylic acid, atorvastatin and ramipril approved in Spain...
February 9, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/27972078/economic-evaluation-of-asa-100mg-simvastatin-40mg-and-ramipril-5-10mg-polypill-for-secondary-prevention-of-cardiovascular-events-in-mexico
#8
L Kaskens, A Gracia, M Rodriguez Mendoza, Y Escobar Juárez, G Mendoza Medrano, H Soto Molina
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27927602/acute-change-in-glomerular-filtration-rate-with%C3%A2-inhibition-of-the-renin-angiotensin-system-does-not%C3%A2-predict-subsequent-renal-and-cardiovascular%C3%A2-outcomes
#9
Catherine M Clase, Joshua Barzilay, Peggy Gao, Andrew Smyth, Roland E Schmieder, Sheldon Tobe, Koon K Teo, Salim Yusuf, Johannes F E Mann
Initiation of blockade of the renin-angiotensin system may cause an acute decrease in glomerular filtration rate (GFR): the prognostic significance of this is unknown. We did a post hoc analysis of patients with, or at risk for, vascular disease, in two randomized controlled trials: Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and the Telmisartan Randomized AssessmeNt Study in ACE iNtolerant participants with cardiovascular Disease (TRANSCEND), whose median follow-up was 56 months...
December 4, 2016: Kidney International
https://www.readbyqxmd.com/read/27909412/modeling-disease-progression-angiotensin-ii-indirectly-inhibits-nitric-oxide-production-via-adma-accumulation-in-spontaneously-hypertensive-rats
#10
Haidong Wang, Hao Jiang, Haochen Liu, Xue Zhang, Guimei Ran, Hua He, Xiaoquan Liu
Nitric oxide (NO) production impairment is involved in the onset and development of hypertension. Although NO production impairment in spontaneously hypertensive rat (SHR) has been reported in a variety of researches, the time course of this progressive procedure, as well as its relationship with asymmetric dimethylarginine (ADMA) and angiotensin II (Ang II), has not been quantified. The aim of this research is to establish a mechanism-based disease progression model to assess Ang II and ADMA's inhibition of NO production in SHR's disease progression with/without ramipril's intervention...
2016: Frontiers in Physiology
https://www.readbyqxmd.com/read/27885499/the-effects-of-alpha-1-adrenoceptor-blockade-and-angiotensin-converting-enzyme-inhibition-on-central-and-brachial-blood-pressure-and-vascular-reactivity-the-doxazosin-ramipril-study
#11
Andreas Jekell, Majid Kalani, Thomas Kahan
We aimed to study whether inhibition of the renin-angiotensin-aldosterone system has effects on vascular structure and function beyond the effects on blood pressure reduction alone. Patients with mild-to-moderate hypertension (n = 61, age 54 ± 12 years, 34% women) received the angiotensin converting enzyme inhibitor ramipril 10 mg or the alpha 1-adrenoceptor blocker doxazosin 8 mg double-blind for 12 weeks. Aortic blood pressure, pulse wave velocity, and augmentation index were assessed by applanation tonometry...
November 24, 2016: Heart and Vessels
https://www.readbyqxmd.com/read/27881888/effects-of-ramipril-and-telmisartan-on-plasma-concentrations-of-low-molecular-weight-and-protein-thiols-and-carotid-intima-media-thickness-in-patients-with-chronic-kidney-disease
#12
Angelo Zinellu, Salvatore Sotgia, Arduino A Mangoni, Elisabetta Sotgiu, Sara Ena, Dionigia Arru, Stefano Assaretti, Angela Baralla, Andrea E Satta, Ciriaco Carru
Hypertension, a common feature in chronic kidney disease (CKD), is an independent risk factor for CKD progression and cardiovascular disease. Although inhibitors of the renin-angiotensin system (RAS) exert salutary effects on blood pressure control and proteinuria in CKD patients, their activity towards traditional and novel oxidative markers is largely unknown. We studied the effects of 6-month treatment with telmisartan versus a combination of telmisartan and ramipril on plasma concentrations of low molecular mass (LMW, including homocysteine and cysteine) and protein thiols (PSH) plasma concentration and their relationships with carotid intima media thickness (IMT), in 24 hypertensive CKD patients (age 60 ± 12 years, 8 females and 16 males)...
2016: Disease Markers
https://www.readbyqxmd.com/read/27875922/no-substantial-gender-differences-in-suspected-adverse-reactions-to-ace-inhibitors-and-arbs-results-from-spontaneous-reporting-system-in-campania-region
#13
Liberata Sportiello, Concetta Rafaniello, Maria Giuseppa Sullo, Mihaela Nica, Cristina Scavone, Francesca Futura Bernardi, Delia Maria Colombo, Francesco Rossi
BACKGROUND: Today, there is a poor knowledge about gender differences in adverse drug reactions (ADRs) to cardiovascular drugs such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Therefore, the aim of this study was to analyze spontaneous reports of suspected ADRs induced by ACE-inhibitors and ARBs, between January 2001 and June 2015, recorded in a Region of Southern Italy (Campania Region). METHODS: We performed a descriptive gender-related analysis of regional safety data, obtained from the spontaneous reporting system...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27856633/effects-of-vitamin-d-receptor-activation-and-dietary-sodium-restriction-on-residual-albuminuria-in-ckd-the-virtue-ckd-trial
#14
Charlotte A Keyzer, G Fenna van Breda, Marc G Vervloet, Maarten A de Jong, Gozewijn D Laverman, Marc H Hemmelder, Wilbert M T Janssen, Hiddo J Lambers Heerspink, Arjan J Kwakernaak, Stephan J L Bakker, Gerjan Navis, Martin H de Borst
Reduction of residual albuminuria during single-agent renin-angiotensin-aldosterone blockade is accompanied by improved cardiorenal outcomes in CKD. We studied the individual and combined effects of the vitamin D receptor activator paricalcitol (PARI) and dietary sodium restriction on residual albuminuria in CKD. In a multicenter, randomized, placebo (PLAC)-controlled, crossover trial, 45 patients with nondiabetic CKD stages 1-3 and albuminuria >300 mg/24 h despite ramipril at 10 mg/d and BP<140/90 mmHg were treated for four 8-week periods with PARI (2 μg/d) or PLAC, each combined with a low-sodium (LS) or regular sodium (RS) diet...
November 17, 2016: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/27807083/therapy-discontinuation-or-substitution-in-patients-with-cardiovascular-disease-switching-among-different-products-of-the-same-off-patent-active-substance-a-real-world-retrospective-cohort-study
#15
Luca Degli Esposti, Diego Sangiorgi, Stefano Buda, Ezio Degli Esposti, Francesco Scaglione
OBJECTIVE: The present study investigated the effects of switching to different products of the same off-patent active substance (brand name or generic) on therapy discontinuation or substitution with another molecule of the same class, in patients with cardiovascular disease treated with statins and antihypertensives in a 'real-world' setting. DESIGN: A retrospective cohort study in a 'real-world' setting. SETTING: Analysis of data performed by integrating administrative databases that included approximately two million individuals who are assisted by the National Health System from three Local Health Units located in three different regions of Italy...
November 2, 2016: BMJ Open
https://www.readbyqxmd.com/read/27798417/efficacy-of-zofenopril-compared-with-placebo-and-other-angiotensin-converting-enzyme-inhibitors-in-patients-with-acute-myocardial-infarction-and-previous-cardiovascular-risk-factors-a-pooled-individual-data-analysis-of-4-randomized-double-blind-controlled-prospective
#16
Claudio Borghi, Stefano Omboni, Giorgio Reggiardo, Stefano Bacchelli, Daniela Degli Esposti, Ettore Ambrosioni
In the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 1, 3, and 4 studies, early administration of zofenopril in acute myocardial infarction showed to be prognostically beneficial versus placebo or ramipril. The SMILE-2 showed that both zofenopril and lisinopril are safe and showed no significant differences in the incidence of major cardiovascular (CV) complications. In this pooled analysis of individual data of the SMILE studies, we evaluated whether the superior efficacy of zofenopril is maintained also in patients with ≥1 CV risk factor (CV+, n = 2962) as compared to CV- (n = 668)...
January 2017: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/27777044/renin-angiotensin-aldosterone-system-inhibitors-in-hypertension-is-there-evidence-for-benefit-independent-of-blood-pressure-reduction
#17
REVIEW
Chirag Bavishi, Sripal Bangalore, Franz H Messerli
The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in the pathogenesis of hypertension (HTN). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are first line anti-HTN drug classes that are potent, effective and largely safe. Direct renin inhibitors (DRIs) have shown similar blood pressure (BP) reduction but more side effects. The efficacy of ACEIs and ARBs (for cardiovascular, cerebrovascular and renal protection) has been promoted to extend beyond what could be explained by BP reduction alone...
November 2016: Progress in Cardiovascular Diseases
https://www.readbyqxmd.com/read/27754253/os-36-04-kruppel-like-factor-15-is-associated-with-cardiac-hypertrophy-in-an-experimental-model-of-kidney-disease
#18
Sheila Patel, Elena Velkoska, Louise Burrell
OBJECTIVE: Left ventricular hypertrophy (LVH) is prevalent in chronic kidney disease (CKD) and a major cause of cardiovascular morbidity and mortality. Treatment of LVH in CKD is based on blood pressure control. The Kruppel like factor 15 (KLF15) is expressed in the heart and acts as a repressor of cardiac hypertrophy and fibrosis. The role of cardiac KLF15 in the development of LVH in rats with CKD secondary to subtotal nephrectomy (STNx) or the effects of ACE inhibition on KLF15 levels has not been addressed previously...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27739363/the-effect-of-treatments-for-rheumatoid-arthritis-on-endothelial-dysfunction-evaluated-by-flow-mediated-vasodilation-in-patients-with-rheumatoid-arthritis
#19
Kazuhiko Kotani, Michiaki Miyamoto, Hitoshi Ando
Rheumatoid Arthritis (RA) is a chronic inflammatory disease with a potential cardiovascular (CV) risk. Flow-Mediated Vasodilation (FMD) is an ultrasonic method to evaluate endothelial function. RA is a contributor to endothelial dysfunction, a CV risk. Relevant insights on the improvement of the CV outcomes in RA patients may be obtained by a systematic review of trials that investigated the effects of RA treatment on FMD in RA patients. This review found that treatments with antirheumatic drugs and some non-antirheumatic drugs could improve the FMD in RA patients...
2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/27731574/azilsartan-novel-angiotensin-receptor-blocker
#20
Ramesh R Dargad, Jai D Parekh, Rohit R Dargad, Shweta Kukrety
OBJECTIVE: To describe the efficacy and safety profile of the new angiotensin receptor blocker (ARB), "Azilsartan Medoxomil", reviewing data available from both clinical and pre-clinical studies. MATERIAL: We completed a review of the English literature from PubMed using the keywords- azilsartan medoxomil, angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitors (ACEi) and hypertension. DATA EVALUATION: Many clinical trials have been conducted comparing the efficacy of azilsartan with other ARB's and also with the ACEi ramipril...
March 2016: Journal of the Association of Physicians of India
keyword
keyword
55573
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"